Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endostatin and Capecitabine with Radiotherapy for Resistant Nasopharyngeal Carcinoma
NCT05514275Phase 2Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Aug 2022
- Primary completion
- Aug 2026
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of endostar in nasopharyngeal carcinoma (NPC), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Recurrence Free Survival at 3 years. Started Aug 2022; status: recruiting.
02
Drugs
endostar
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT05514275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05514275.